ARTICLE | Company News
Moderna, AZ in relaxin mRNA therapeutic deal
November 30, 2017 11:43 PM UTC
Moderna Therapeutics Inc. (Cambridge, Mass.) and AstraZeneca plc (LSE:AZN; NYSE:AZN) partnered to co-develop and co-commercialize AZD7970, which is in preclinical testing to treat heart failure. Moderna will be responsible for preclinical development, while AZ is to conduct early clinical development. The partners will share late-stage clinical development costs and share U.S. profits equally. The pharma will lead commercialization outside the U.S., where Moderna is eligible for tiered royalties up to double-digits...